PD-1: A new candidate target for analgesic peptide design.

[1]  Xiaojun Yao,et al.  An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Craig M. Williams,et al.  Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources , 2022, Journal of Medicinal Chemistry.

[3]  J. Savage,et al.  Emerging Role of PD-1 in the Central Nervous System and Brain Diseases , 2021, Neuroscience Bulletin.

[4]  Yulong Sun,et al.  Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception. , 2020, Journal of medicinal chemistry.

[5]  Yu-Qiu Zhang,et al.  Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia , 2020, JCI insight.

[6]  R. Ji,et al.  PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia , 2020, iScience.

[7]  I. Vetter,et al.  Pharmacology and Therapeutic Potential of Venom Peptides. , 2020, Biochemical pharmacology.

[8]  L. Gentilucci,et al.  Functional Selectivity and Antinociceptive Effects of a Novel KOPr Agonist , 2020, Frontiers in Pharmacology.

[9]  R. Ji,et al.  Anti–PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates , 2020, Science Translational Medicine.

[10]  S. Shi,et al.  PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model , 2020, Cephalalgia : an international journal of headache.

[11]  E. Novellino,et al.  POTENT, EFFICACIOUS AND STABLE CYCLIC OPIOID PEPTIDES WITH LONG LASTING ANTINOCICEPTIVE EFFECT AFTER PERIPHERAL ADMINISTRATION. , 2019, Journal of medicinal chemistry.

[12]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[13]  R. Lewis,et al.  Structure–Function and Therapeutic Potential of Spider Venom-Derived Cysteine Knot Peptides Targeting Sodium Channels , 2019, Front. Pharmacol..

[14]  J. Eichler.  Protein glycosylation , 2019, Current Biology.

[15]  T. Okazaki,et al.  PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation , 2019, Front. Immunol..

[16]  Bin Liu,et al.  PD‐1‐expressing B cells suppress CD4+ and CD8+ T cells via PD‐1/PD‐L1‐dependent pathway , 2019, Molecular immunology.

[17]  K. Chandy,et al.  Antibodies and venom peptides: new modalities for ion channels , 2019, Nature Reviews Drug Discovery.

[18]  B. Olivera,et al.  Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways. , 2019, Journal of proteomics.

[19]  A. Ferrer-Montiel,et al.  Recent progress in non-opioid analgesic peptides. , 2018, Archives of biochemistry and biophysics.

[20]  R. Ferris,et al.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients , 2018, Cancer Immunology Research.

[21]  A. Dömling,et al.  Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? , 2018, Angewandte Chemie.

[22]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[23]  J. Morgenweck,et al.  Novel Endomorphin Analogs Are More Potent and Longer-Lasting Analgesics in Neuropathic, Inflammatory, Postoperative, and Visceral Pain Relative to Morphine. , 2017, The journal of pain : official journal of the American Pain Society.

[24]  M. Topf,et al.  The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Nav1.7 , 2017, Journal of the American Chemical Society.

[25]  E. Novellino,et al.  Cyclic Biphalin Analogues Incorporating a Xylene Bridge: Synthesis, Characterization, and Biological Profile. , 2017, ACS medicinal chemistry letters.

[26]  Yong Ho Kim,et al.  PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1 , 2017, Nature Neuroscience.

[27]  Jolene L. Lau,et al.  From Natural Peptides to Market , 2017 .

[28]  Sakshi Sachdeva.  Peptides as ‘Drugs’: The Journey so Far , 2016, International Journal of Peptide Research and Therapeutics.

[29]  T. Anagnostou,et al.  The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation , 2016, Front. Immunol..

[30]  Rui Wang,et al.  Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities. , 2016, Journal of medicinal chemistry.

[31]  Yu-Qiu Zhang,et al.  Pain regulation by non-neuronal cells and inflammation , 2016, Science.

[32]  Henry Lin,et al.  Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.

[33]  G. Tibbs,et al.  Voltage-Gated Ion Channels in the PNS: Novel Therapies for Neuropathic Pain? , 2016, Trends in pharmacological sciences.

[34]  J. Morgenweck,et al.  Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine , 2016, Neuropharmacology.

[35]  F. Simonin,et al.  Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. , 2016, Journal of medicinal chemistry.

[36]  V. Hruby,et al.  Cyclic Opioid Peptides. , 2016, Current medicinal chemistry.

[37]  P. Ricciardi-Castagnoli,et al.  PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity , 2016, Oncoimmunology.

[38]  K. Zak,et al.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. , 2015, Structure.

[39]  V. Hruby,et al.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. , 2015, Journal of medicinal chemistry.

[40]  Z. Szewczuk,et al.  N‐terminal guanidinylation of the cyclic 1,4‐ureido‐deltorphin analogues: the synthesis, receptor binding studies, and resistance to proteolytic digestion , 2015, Journal of Peptide Science.

[41]  R. Raffa,et al.  Delta opioid agonists: a concise update on potential therapeutic applications , 2015, Journal of clinical pharmacy and therapeutics.

[42]  Fengyu Liu,et al.  Shp-1 dephosphorylates TRPV1 in dorsal root ganglion neurons and alleviates CFA-induced inflammatory pain in rats , 2015, Pain.

[43]  Peter Kreiner,et al.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. , 2015, Annual review of public health.

[44]  C. Stevens.  Bioinformatics and evolution of vertebrate nociceptin and opioid receptors. , 2015, Vitamins and hormones.

[45]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[46]  E. Novellino,et al.  Novel cyclic biphalin analogue with improved antinociceptive properties. , 2014, ACS medicinal chemistry letters.

[47]  A. Basbaum,et al.  Transmitting Pain and Itch Messages: A Contemporary View of the Spinal Cord Circuits that Generate Gate Control , 2014, Neuron.

[48]  L. Tang,et al.  Programmed Death 1 Deficiency Induces the Polarization of Macrophages/Microglia to the M1 Phenotype After Spinal Cord Injury in Mice , 2014, Neurotherapeutics.

[49]  I. Toth,et al.  Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain , 2013, Front. Pharmacol..

[50]  P. Schiller,et al.  N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile. , 2013, Bioorganic & medicinal chemistry letters.

[51]  Mark Sanford,et al.  Intrathecal Ziconotide: A Review of Its Use in Patients with Chronic Pain Refractory to Other Systemic or Intrathecal Analgesics , 2013, CNS Drugs.

[52]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[53]  Rui Wang,et al.  Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs , 2012, Medicinal research reviews.

[54]  J. V. Aldrich,et al.  Opioid Peptides: Potential for Drug Development. , 2012, Drug discovery today. Technologies.

[55]  É. Marsault,et al.  Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.

[56]  P. Kosson,et al.  PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects , 2010, Molecular pain.

[57]  Loise M. Francisco,et al.  Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. , 2009, Investigative ophthalmology & visual science.

[58]  C. Chung,et al.  PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis , 2009, Proceedings of the National Academy of Sciences.

[59]  Duncan Patrick McGregor,et al.  Discovering and improving novel peptide therapeutics. , 2008, Current opinion in pharmacology.

[60]  N. Franks.  General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal , 2008, Nature Reviews Neuroscience.

[61]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[62]  E. Villegas,et al.  Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs. , 2007, Natural product reports.

[63]  Hong‐Mei Liu,et al.  Utilization of Combined Chemical Modifications to Enhance the Blood-Brain Barrier Permeability and Pharmacological Activity of Endomorphin-1 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[64]  Graeme Henderson,et al.  75 years of opioid research: the exciting but vain quest for the Holy Grail , 2006, British journal of pharmacology.

[65]  Michael Cammer,et al.  Structural and functional analysis of the costimulatory receptor programmed death-1. , 2004, Immunity.

[66]  Ronald T. Borchardt,et al.  Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood–Brain Barrier Permeability of Peptides , 1994, Pharmaceutical Research.

[67]  L. Gentilucci.  New trends in the development of opioid peptide analogues as advanced remedies for pain relief. , 2004, Current topics in medicinal chemistry.

[68]  S. Sakurada,et al.  Synthesis and antinociceptive activity of orally active opioid peptides: improvement of oral bioavailability by esterification. , 2003, Chemical & pharmaceutical bulletin.

[69]  A. Lipkowski,et al.  Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. , 2002, Journal of pharmaceutical sciences.

[70]  V. Hruby,et al.  The effect of halogenation on blood–brain barrier permeability of a novel peptide drug☆ , 1999, Peptides.

[71]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[72]  M. Taniwaki,et al.  Structure and chromosomal localization of the human PD-1 gene (PDCD1). , 1994, Genomics.

[73]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[74]  P. Schiller,et al.  Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high mu opioid receptor selectivity. , 1989, Journal of medicinal chemistry.